Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Markman Proposes Shift in Ovarian Cancer Clinical Trial Paradigm

January 16th 2018

Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer.

Dr. Sessa on the Management of BRCA1/2 Mutations in Ovarian Cancer

January 11th 2018

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses the management of BRCA1/2 mutations in patients with ovarian cancer.

Dr. Sehouli Discusses Unmet Needs in Ovarian Cancer

January 8th 2018

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses the unmet needs for patients with ovarian cancer.

Letrozole Maintenance Therapy Improves RFS in Ovarian Cancer

January 4th 2018

Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.

Dr. Ledermann Discusses Patient Selection in Ovarian Cancer

January 3rd 2018

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses patient selection in the treatment of patients with ovarian cancer.

Targeting Tumor Vasculature in Ovarian Cancer

December 28th 2017

Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.

Unmet Needs in Ovarian Cancer

December 23rd 2017

Evolving Role of PARP Inhibitors in Ovarian Cancer

December 23rd 2017

PARP Inhibitor Side Effect Management in Ovarian Cancer

December 23rd 2017

Ovarian Cancer: Deciding Among PARP Inhibitors

December 23rd 2017

Ovarian Cancer Decisions: Treatment Versus Maintenance

December 23rd 2017

Talking With Patients About Recurrence Risk in Ovarian Cancer

December 23rd 2017

Ovarian Cancer: Making Treatment Plans Together

December 23rd 2017

Options With Genetic Testing in Ovarian Cancer

December 23rd 2017

Platinum Sensitivity and PARP Inhibition in Ovarian Cancer

December 23rd 2017

Ovarian Cancer: Talking to Patients About PARP Inhibitors

December 23rd 2017

Future of Immunotherapy in Ovarian Cancer to Include Combinations

December 22nd 2017

Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.

Dr. Markman on the Era of Precision Medicine in Ovarian Cancer

December 19th 2017

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the era of precision medicine in ovarian cancer.

Dr. Levine on Sequencing of Agents for Ovarian Cancer

December 14th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Dr. Monk Discusses Immunotherapy in Ovarian Cancer

December 12th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for the treatment of patients with ovarian cancer.